Heidelberg Pharma AG has undergone significant leadership changes with the immediate revocation of Professor Andreas Pahl's appointment as Executive Management Board member and Chief Executive Officer, replaced by Dr. Dongzhou Jeffery Liu as Chairman of the Executive Management Board and new Chief Executive Officer. The Supervisory Board made these changes effective immediately, marking a pivotal transition for the clinical-stage biotech company specializing in Antibody Drug Conjugate development.
Dr. Liu's appointment follows his resignation from the Supervisory Board, with his permanent role as Chairman and CEO becoming effective December 24, 2025. During the transition period until December 23, 2025, he will serve as a deputy member to the Executive Management Board under section 105 (2) of the German Stock Corporation Act. Dr. Karl Benedikt Biesinger, Chairman of the Supervisory Board, acknowledged Professor Pahl's contributions, particularly his scientific expertise in developing the company's unique Amanitin-based ADC technology that advanced the lead clinical stage project HDP-101.
The leadership change carries significant implications for Heidelberg Pharma's strategic direction and investor confidence. Dr. Liu brings extensive pharmaceutical industry experience spanning more than 25 years, including his current role as Chief Scientific Officer and President of Huadong Global Development at Huadong Medicine in China. His background includes senior positions at major pharmaceutical companies including GlaxoSmithKline, Wyeth (now Pfizer), and Forest Labs (now Abbvie), with expertise covering clinical and preclinical research & development of medicinal products, including ADC products.
This leadership transition matters because it occurs at a critical juncture for Heidelberg Pharma's cancer treatment pipeline. The company's ATAC technology represents a novel approach in oncology, being the first to utilize Amanitin from the green death cap mushroom in cancer therapy. Dr. Liu expressed confidence in the technology's potential, citing promising clinical data with HDP-101, the lead candidate targeting multiple myeloma that has received Orphan Drug Designation and Fast Track Designation from the FDA.
The implications extend beyond corporate governance to patient care and cancer treatment advancement. Heidelberg Pharma's technology platform addresses a significant unmet medical need through Antibody Drug Conjugates that combine antibody specificity with toxin efficacy to target cancer cells. The company's pipeline includes HDP-102 in clinical development for Non-Hodgkin Lymphoma, along with HDP-103 for metastatic castration-resistant prostate cancer and HDP-104 for gastrointestinal tumors completing preclinical development.
For the biotechnology industry and cancer patients worldwide, this leadership change signals potential acceleration in developing next-generation ADC therapies. The appointment of an executive with Dr. Liu's international experience and ADC expertise could enhance Heidelberg Pharma's global partnerships and development capabilities. Investors and industry observers can monitor the company's progress through its Frankfurt Stock Exchange listing under symbol HPHA, with additional information available at www.heidelberg-pharma.com.
